CHICAGO — Financial toxicity associated with cancer diagnoses appeared to be a common theme at the ASCO Annual Meeting, according to Brian Bolwell, MD, chairman of the Taussig Cancer Institute of Cleveland Clinic Foundation.
In particular, Bolwell found the lack of reimbursement for next-generation sequencing of concern.
The high cost of therapy that puts patients at risk for financial toxicity, in combination with the fact that next-generation sequencing often is not reimbursed, “is a combination of several bad factors, and unfortunately remain unaddressed in terms of how to find an adequate solution for our patients and their families.,” he said. – by Kristie L. Kahl
Disclosure: Bolwell reports no relevant financial disclosures.